Skip to main content
Caplight Logo









Sanguine Biosciences

Sanguine Biosciences

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://sanguinebio.com/

Last Round

Debt

Nov 1, 2023

Total Funding Raised

$10.22M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Sanguine Biosciences is a biotechnology company that provides a platform for direct-to-patient engagement and in-home collection of annotated biospecimens for research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

human biospecimensbiospecimen procurementleukopakbiobankPBMCperipheral blood mononuclear cellscell and gene therapyin-home sample collectiondrug discoverymobile phlebotomyimmunology researchoncology researchprospective collectionrecallable donorsbiomarker validationlaboratory servicesbiorepository

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sanguine Biosciences Comparables

Compare Sanguine Biosciences with similar companies based on industry and business-model similarity.

Sanguine Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CGT Global
87%
Audubon Bioscience
85%
ProteoGenex, Inc.
85%

Sanguine Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtNov 1, 2023
VC RoundJan 9, 2023
GrantFeb 26, 2019
SeedMar 7, 2013

Key People

Founding team and executive leadership

Brian Neman

Founder, CEO, Board Member

Founding Team

Gerald Lee

Chief Product Officer

Executive Team

Sanguine Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 3, 2026

    Open roles increased to 207, 2.6x the trailing average.

  • Jul 20, 2026

    Open roles increased to 205, 12.1x the trailing average.

Sanguine Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sanguine Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sanguine Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range73
Year Founded2010
Last FundingNov 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?